Dennis Slamon

Q: What Schools Are Affiliated With Dennis Slamon

Dennis Slamon is affiliated with the following schools: University of Liège, University of Alberta, University of Newcastle , University of Tokyo, University of California, Los Angeles, University of Southern California, University of Chicago, University of Hamburg, University of Basel, Seoul National University, Washington & Jefferson College, McGill University, Ohio State University, University of Miami

Dennis Slamon's AcademicInfluence.com Rankings

Dennis Slamon

Philosophy

#3203

World Rank

#5239

Historical Rank

#1039

USA Rank

Logic

#1113

World Rank

#1765

Historical Rank

#362

USA Rank

philosophy Degrees

Download Badge

Philosophy

Dennis Slamon's Degrees

Masters Medicine University of Chicago
PhD Biochemistry University of Chicago

Why Is Dennis Slamon Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dennis Joseph Slamon , is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.

(See a Problem?)

Dennis Slamon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. (1987) (11735)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (2001) (10106)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. (1989) (6994)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2002) (3080)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. (1999) (2850)
Palbociclib and Letrozole in Advanced Breast Cancer. (2016) (1641)
Expression of a multidrug-resistance gene in human tumors and tissues. (1987) (1529)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. (2015) (1379)
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers (1998) (1230)
Adjuvant trastuzumab in HER2-positive breast cancer. (2011) (1199)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (2009) (1158)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma (2010) (1123)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. (2006) (911)
Expression of cellular oncogenes in human malignancies. (1984) (829)
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. (1997) (825)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2015) (750)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers (1999) (710)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. (1990) (642)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. (2003) (614)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018) (580)
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. (1994) (537)
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. (2015) (534)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. (2004) (516)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2016) (516)
Smart drugs: tyrosine kinase inhibitors in cancer therapy. (2002) (510)
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. (2009) (507)
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse (1982) (494)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. (1994) (480)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. (2006) (474)
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas (1999) (450)
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. (2003) (447)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. (2016) (425)
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. (2009) (424)
Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro (2007) (408)
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. (2002) (407)
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial (1998) (405)
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs (1998) (400)
Adjuvant Trastuzumab in HER 2-Positive Breast Cancer (2011) (383)
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells (1997) (364)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (2019) (354)
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. (2005) (349)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib (2010) (320)
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. (1999) (315)
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials (2005) (306)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. (2004) (291)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. (2004) (277)
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. (2014) (276)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (2018) (269)
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. (1990) (266)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer (2011) (262)
HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer (1997) (260)
Amplification of c-erbB-2 and aggressive human breast tumors? (1988) (254)
Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients (2004) (253)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. (2015) (250)
Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues (1990) (248)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers (2016) (247)
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. (2001) (246)
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. (2006) (245)
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy (2004) (237)
Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. (1994) (236)
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. (1996) (234)
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. (2000) (227)
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. (1993) (218)
Frequency and structure of p53 rearrangements in human osteosarcoma. (1990) (213)
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic (1991) (209)
First-Line Herceptin® Monotherapy in Metastatic Breast Cancer (2001) (207)
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. (1999) (201)
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Δ11b (1997) (200)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo (2010) (198)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Trastuzumab and chemotherapeutics: drug interactions and synergies. (2000) (194)
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. (1992) (190)
Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells (2012) (187)
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. (1984) (184)
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. (2001) (179)
Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. (1991) (179)
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development (2004) (173)
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer (2002) (171)
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. (1990) (167)
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. (2017) (166)
Transcription of c-onc genes c-rasKi and c-fms during mouse development (1983) (165)
prk, a Cytokine-inducible Human Protein Serine/Threonine Kinase Whose Expression Appears to be Down-regulated in Lung Carcinomas* (1996) (165)
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. (2004) (163)
Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. (2001) (161)
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. (2011) (156)
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies (2005) (156)
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. (2006) (155)
Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. (1995) (154)
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. (2000) (152)
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells (1999) (152)
The x gene is essential for HTLV replication. (1985) (149)
Studies of the HER-2/neu proto-oncogene in human breast cancer. (1990) (148)
Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. (1993) (146)
Cyclin D1 Amplification and p16(MTS1/CDK4I) Deletion Correlate With Poor Prognosis in Head and Neck Tumors (2002) (144)
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. (2013) (144)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period (2008) (144)
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 (2016) (143)
FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells (2012) (139)
Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas (1997) (137)
Proto-oncogenes and human cancers. (1987) (137)
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer (2013) (134)
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. (2002) (134)
p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. (1994) (134)
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. (2011) (133)
Radiolabeled antibody targeting of the HER-2/neu oncoprotein. (1992) (132)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. (2016) (132)
Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. (1995) (130)
Cycling cancer persister cells arise from lineages with distinct programs (2021) (129)
Expression of p21 ras oncoproteins in human cancers. (1986) (128)
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer (1999) (126)
Studies of the human c-myb gene and its product in human acute leukemias. (1986) (121)
Identification and characterization of the protein encoded by the human N-myc oncogene. (1986) (120)
Expression of cellular oncogenes during embryonic and fetal development of the mouse. (1984) (116)
Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. (1991) (114)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study (2019) (110)
Regulation of expression of human granulocyte/macrophage colony-stimulating factor. (1986) (107)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2017) (106)
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials (2016) (105)
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). (2016) (105)
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT (2014) (104)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (102)
Periostin promotes ovarian cancer angiogenesis and metastasis. (2010) (102)
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer (2019) (102)
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. (2014) (101)
Cardiovascular Risk Profile of Patients with HER2/neu-Positive Breast Cancer Treated with Anthracycline-Taxane–Containing Adjuvant Chemotherapy and/or Trastuzumab (2007) (100)
Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. (1988) (100)
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer (2014) (99)
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. (2010) (98)
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. (2013) (98)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer (2019) (97)
The role of genetic breast cancer susceptibility variants as prognostic factors. (2012) (95)
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. (2000) (95)
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer (2005) (92)
Shaping the future of biomarker research in breast cancer to ensure clinical relevance (2007) (90)
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. (2001) (88)
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer (2013) (87)
Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. (2000) (86)
A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3. (2002) (85)
HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. (1990) (85)
Studies of the putative transforming protein of the type I human T-cell leukemia virus. (1985) (83)
Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum (2018) (82)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
Evaluation of well‐differentiated/de‐differentiated liposarcomas by high‐resolution oligonucleotide array‐based comparative genomic hybridization (2011) (80)
3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. (2006) (79)
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. (2014) (79)
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. (2001) (78)
Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia. (1988) (78)
Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. (1988) (78)
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) (2013) (77)
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial (2017) (76)
Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. (2009) (76)
Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds* (2008) (75)
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. (1993) (75)
Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens. (1985) (73)
Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation (2010) (72)
ERCC5 is a novel biomarker of ovarian cancer prognosis. (2008) (71)
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer (2013) (70)
Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells (2013) (70)
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib (2012) (68)
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 (2002) (68)
Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her‐2/neu oncogene (1991) (66)
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation (2001) (66)
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth (2013) (65)
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines (2010) (65)
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). (2017) (64)
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer (2018) (61)
Prognostic gene expression signature for high-grade serous ovarian cancer (2020) (61)
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells (2004) (60)
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) (2014) (60)
HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. (1988) (60)
A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV‐I and HIV‐1: A clinical and molecular analysis (1989) (59)
Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis (2011) (59)
Proto-oncogenes and tumor suppressor genes in human urological malignancies. (1994) (59)
HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells (2005) (58)
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance (2015) (58)
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines (2018) (58)
Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis (2019) (57)
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer (2008) (57)
Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression* (2014) (56)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer (2020) (56)
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer (2010) (55)
HER2 testing and correlation with efficacy of trastuzumab therapy. (2002) (55)
HER-2/neu oncogene amplification and expression in breast and ovarian cancers. (1990) (55)
Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. (1992) (54)
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer (2013) (53)
An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells (2017) (53)
Studies of the retinoblastoma gene in human sarcomas. (1989) (51)
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. (2018) (50)
RIN1 is a breast tumor suppressor gene. (2007) (50)
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) (2020) (50)
FOXO1A is a target for HER2-overexpressing breast tumors. (2010) (50)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (2018) (48)
Monoclonal antibody therapy for breast cancer: herceptin. (2003) (48)
Advances in adjuvant therapy for breast cancer. (2006) (48)
A significant association of Ha‐ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases (1991) (47)
Erratum: Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (Cell (2015) 162(5) (974–986) (S009286741500848X) (10.1016/j.cell.2015.07.011)) (2017) (46)
A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. (1998) (46)
Mutations of the p53 gene are not detectable in human testicular tumors. (1994) (46)
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer (2019) (46)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. (2019) (44)
Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro (2013) (44)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (2016) (44)
Pleiotrophin mediates hematopoietic regeneration via activation of RAS. (2014) (44)
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors (2010) (44)
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer (2013) (43)
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. (2015) (43)
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response (2015) (43)
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy (2014) (42)
Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene (2001) (41)
Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer (2014) (41)
Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy (2014) (40)
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study (2012) (40)
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target (2008) (40)
A human ovarian carcinoma murine xenograft model useful for preclinical trials. (2002) (39)
p53 mutations and MDM-2 amplification in renal cell cancers. (1994) (39)
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer (2013) (39)
Expression of protooncogene c-myb in normal human hematopoietic cells (1989) (38)
Detection of antibodies to human T‐lymphotropic virus type 1 (HTLV‐1) (1988) (35)
RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. (2010) (34)
Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I (1988) (34)
Human c-FES is a nuclear tyrosine kinase. (1995) (34)
Identification of conserved amino acids in the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit critical for function. Evidence for formation of a heterodimeric receptor complex prior to ligand binding. (1994) (33)
First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. (2001) (33)
Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). (2019) (32)
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib (2016) (32)
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics (2014) (31)
PIAS1 Regulates Breast Tumorigenesis through Selective Epigenetic Gene Silencing (2014) (31)
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. (2018) (30)
First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors (2007) (30)
HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. (1987) (30)
Expression of protooncogene c-myb in normal human hematopoietic cells. (1989) (30)
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) (2020) (29)
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. (2009) (29)
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples (2001) (29)
Expression of Wnt 3 activates Wnt / β-catenin pathway and promotes EMT-like phenotype in trastuzumab resistant HER 2-overexpressing breast cancer cells (2012) (29)
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. (2020) (29)
Identification of new gene products coded from X regions of human T-cell leukemia viruses. (1985) (28)
The Transmembrane Heregulin Precursor Is Functionally Active* (2001) (28)
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response (2020) (28)
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) (2020) (27)
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors? (1988) (27)
Role for polo-like kinase 4 in mediation of cytokinesis (2019) (27)
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer (2019) (27)
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient (2015) (27)
Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. (2002) (26)
Oncogenes: implications for the diagnosis and treatment of cancer. (1984) (26)
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer (2001) (25)
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09) (2018) (25)
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. (2004) (25)
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial (2019) (25)
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53 (2013) (25)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. (2015) (24)
Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines (2020) (24)
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi (2017) (23)
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines (2018) (23)
A model-based approach for assessing in vivo combination therapy interactions. (1999) (22)
Systemic therapy for metastatic renal cell carcinoma: a review and update. (2012) (22)
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. (2000) (22)
Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. (2001) (22)
ADRM1‐amplified metastasis gene in gastric cancer (2015) (21)
A careful reassessment of anthracycline use in curable breast cancer (2021) (20)
Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins (1986) (20)
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. (2013) (20)
Significance of tumor‐associated autoantibodies in the early diagnosis of lung cancer (2018) (19)
Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer. (1994) (19)
Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). (2020) (18)
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. (2016) (17)
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL (2018) (17)
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. (1998) (16)
Studies of the HER-2/neu Proto-Oncogene in Human Breast Cancer (1989) (16)
Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. (1988) (16)
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo (2019) (16)
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK (2011) (16)
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. (1996) (16)
MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer (2018) (15)
Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 ) (2006) (15)
The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers. (2007) (14)
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). (2021) (14)
Organ specific expression of ras oncoproteins during growth and development of the rat (1986) (14)
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. (2013) (14)
Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015) (14)
INTRODUCTION Translational Research: The Role of VEGF in Tumor Angiogenesis (2000) (13)
Health-related quality of life (HRQL) in women with HER2-positive metastatic breast cancer: effect of treatment with trastuzumab (Herceptin) plus chemotherapy versus chemotherapy alone (2001) (13)
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials (2020) (13)
N-myc protein expression in small round cell tumors. (1988) (13)
Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. (2005) (12)
Overexpressing This Oncogene Radiosensitivity of Human Breast Cancer Cells of Radiation-induced DNA Damage and Enhances Receptor Modulates Repair neu Monoclonal Antibody to HER-2/ (1999) (12)
Expression of the nm23 gene and breast cancer prognosis. (1991) (12)
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). (2010) (11)
Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programs (2020) (11)
Translational Research: the Role of VEGF in Tumor Angiogenesis. Proceedings of a symposium. Washington, DC, USA. November 16, 1999. (2000) (11)
Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398in vitro (2012) (11)
Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. (1998) (11)
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18). (2015) (10)
Tissue microarrays from frozen tissues-OCT technique. (2010) (10)
Neratinib to inhibit the growth of triple-negative breast cancer cells. (2015) (9)
Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). (2013) (9)
Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias. (2005) (9)
Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus (2008) (9)
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 (2016) (9)
Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). (2021) (9)
UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer. (1990) (8)
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial. (2013) (8)
Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. (2020) (7)
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? (2003) (7)
Reply to E.H. Hammond et al (2009) (7)
N-myc protein expression by neuroblastoma cells that have metastasized to bone marrow. (1988) (7)
INSERTION OF NEW GENETIC INFORMATION INTO BONE MARROW CELLS OF MICE: COMPARISON OF TWO SELECTABLE GENES * (1982) (7)
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. (2020) (7)
Abstract B31: Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab resistant HER2-overexpressing breast cancer cells. (2012) (7)
Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity. (2017) (7)
Abstract PD2-08: Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study (2020) (6)
Chemical Therapeutics The HSP 90 Inhibitor NVP-AUY 922 Potently Inhibits Non – Small Cell Lung Cancer Growth (2013) (6)
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer (2019) (6)
Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer (1999) (6)
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. (2014) (6)
Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer. (2004) (6)
Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of herceptin (2001) (6)
Inhibition of HSP 90 with AUY 922 Induces Synergy in HER 2-Ampli fi ed Trastuzumab-Resistant Breast andGastric Cancer (2013) (6)
Older (age > 60 years) patients obtain survival benefit from herceptin plus chemotherapy (2001) (6)
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer (2014) (5)
Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy (2017) (5)
Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells (2018) (5)
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. (2019) (5)
BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition (2018) (5)
Protective effect of the double-stranded polyribonucleotide, polyinosinic polycytidylic acid, against rat erythroblastosis induced by murine erythroblastosis virus. (1973) (5)
Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors (2016) (5)
Biologic effects of CP-724,714, a selective HER-2/neu kinase inhibitor, on human breast cancer cells with variable expression of EGFR and HER-2 (2004) (5)
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial. (2015) (5)
Reply to V. Arena et al (2009) (5)
Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies (2016) (5)
A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. (2011) (5)
Shaping the future of biomarker research (2007) (5)
Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01) (2008) (5)
Biologic Approaches to Managing Advanced Breast Cancer. (1999) (5)
317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies (2015) (4)
Abstract PD3-12: Central nervous system as first site of relapse in patients with HER2 positive early breast cancer treated in the BCIRG-006 trial (2019) (4)
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy (2021) (4)
293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases (2020) (4)
Abstract 1321: Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma (2014) (4)
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. (2019) (4)
Human Breast Cancer : Correlation of Relapse and Survival with Amplification of the HER-2 lneu Oncogene (2011) (4)
Comparison of the transActivation Capabilities of the Human T-Cell Leukemia Virus Type I and II X Proteins (4)
Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials (2022) (4)
Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma. (2013) (4)
Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum (2018) (4)
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. (2022) (4)
Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (4)
Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes. (2005) (3)
Cell type-specific expressions of c-ras gene products in the normal rat (1987) (3)
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3. (2017) (3)
Hemolytic anemia induced by murine erythroblastosis virus: possible mechanisms of hemolysis and effects of an interferon inducer. (1975) (3)
Insertion of drug resistance genes in animals (1982) (3)
Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis (2020) (3)
Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib (2012) (3)
Phase II study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC). (2006) (3)
Abstract 25: PD 0332991, a selective CDK 4/6 inhibitor, preferentially inhibits growth of ovarian cancer cells with high Rb and low p16 (CDKN2A) expression (2010) (3)
Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients. (2022) (3)
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022) (3)
Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (3)
The Molecular Biology of HER2 and HER2-Targeted Therapies (2019) (3)
A chemically-modified miR-21 inhibitor (ADM-21) as a novel potential therapy in bladder cancer. (2017) (3)
Abstract 3589: Dovitinib (TKI258), a multikinase inhibitor of FGFR, PDGFR, and VEGFR tyrosine kinases, induces growth inhibition in endometrial carcinoma cells (2011) (3)
Cardiovascular risk profile of breast cancer patients treated with anthracycline-taxane containing adjuvant chemotherapy and/or trastuzumab. (2006) (3)
Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer (2016) (2)
HER2 Testing in the Era of Changing Guidelines (2019) (2)
Abstract 3008: Preclinical characterization of AMG 900, a pan-aurora kinase inhibitor, alone and in combination with taxanes in ovarian cancer (2016) (2)
A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06). (2020) (2)
Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies (2015) (2)
P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001 (2018) (2)
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib (2022) (2)
Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations (2020) (2)
Breast Cancer Trials (2001) (2)
Inhibition of the HER-2/neu Oncogene: A Translational Research Model for the Development of Future Targeted Therapies (2002) (2)
Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology (2012) (2)
Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BC (2006) (2)
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC). (2022) (2)
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023) (2)
HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials. (2016) (2)
Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (2)
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis (2022) (2)
Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models (2019) (2)
Role and therapeutic targeting of miR-21 in bladder cancer. (2015) (2)
620PDPROTON PUMP INHIBITOR (PPIS) THERAPY MAY IMPAIR CAPECITABINE (CAPE) EFFICACY IN METASTATIC GASTROESOPHAGEAL CANCER (GEC), RESULTS FROM THE TRIO-013/LOGIC TRIAL. (2014) (2)
Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells. (2013) (2)
Abstract 4557: Expression of p16 in colon cancer and cyclin D1 in gastric cancer predicts response to CDK4/6 inhibitionin vitro (2014) (2)
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. (2015) (2)
Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. (2012) (2)
Preclinical studies with neratinib in triple-negative breast cancer. (2013) (2)
The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. (2015) (2)
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. (2013) (2)
557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer (2008) (1)
BRCA1 promoter methylation in breast cancer cell lines and primary tumors (2007) (1)
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). (2020) (1)
145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer (2012) (1)
Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells. (2006) (1)
Abstract 3041: CD72 as a potential new therapeutic target in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) (2019) (1)
Abstract 2437: MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status. (2013) (1)
Abstract 5634: Increased co-amplification of HER2 and STARD3 in a cell line model of acquired lapatinib resistance. (2013) (1)
Controversies in HER 2 Oncogene Testing : What Constitutes a True Positive Result in Patients With Breast Cancer ? (2018) (1)
Fluorescence in situ hybridization (FISH) may accurately identify patients who obtain survival benefit from herceptin plus chemotherapy (2001) (1)
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer (2009) (1)
Expression of p 21 ras Oncoproteins in Human Cancers 1 (2006) (1)
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy (2014) (1)
Oncogenes in clinical cancer — A panel discussion (1987) (1)
Herceptin (R) plus cisplatin is active in patients with metastatic breast cancer (1999) (1)
Expression of the hst-l and c-kit Protooncogenes in Human Testicular Germ Cell Tumors1 (2006) (1)
HSP90 inhibition in HER2-positive breast cancer cells. (2009) (1)
Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies (2022) (1)
Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx). (2015) (1)
Abstract 612: FOXO1A is a target for HER2 overexpressing breast tumors (2010) (1)
Abstract LB-70:In vitroanti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel of human breast cancer cell lines (2010) (1)
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study (2012) (1)
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor (2022) (1)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers (2016) (1)
Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers (2022) (1)
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL (2018) (1)
Chemical Therapeutics Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib ( TKI 258 ) and NVP-BGJ 398 in Human Endometrial Cancer Cells (2013) (1)
Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. (2018) (1)
Abstract 1385: Molecular changes in breast tumors following bevacizumab-based treatment: Final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage II or III breast cancer (2012) (1)
Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter. (2005) (1)
Abstract LB-257: Ganitumab (AMG 479), an anti IGF-1R antibody, inhibits the proliferation of melanoma cells (2012) (1)
612 PD-0332991, AN INHIBITOR OF CYCLIN-DEPENDENT KINASE 4/6, DEMONSTRATES INHIBITION OF PROLIFERATION IN RENAL CELL CARCINOMA AT NANOMOLAR CONCENTRATIONS AND MOLECULAR MARKERS PREDICT FOR SENSITIVITY (2013) (1)
Abstract P5-19-19: Impact of adding palbociclib to letrozole on pain severity and pain interference with various activities of daily life in patients with ER+, HER2- metastatic breast cancer as first line treatment (2015) (1)
Frontiers in HER2-positive breast cancer in 2020. (2021) (1)
Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) (0)
Abstract A97: Loss of function for FOXO1A contributes to poor outcome in African American and Latina women with breast cancer (2010) (0)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
Cancer Therapy : Preclinical Ganitumab ( AMG 479 ) Inhibits IGF-II – Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy (2014) (0)
PRESIDENTIAL FORUM Cancer Research in the 21st Century (2016) (0)
Expression of Immediate Early Transcription Factors in Human Renal Cell Tumors (1994) (0)
Signaling and Regulation Expression of Wnt 3 Activates Wnt / b-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER 2-Overexpressing Breast Cancer Cells (2012) (0)
Abstract #4725: Enhanced expression of AREG and FGFR2 and increased activity of peptide growth factor signaling pathways induces resistance to fulvestrant and tamoxifen (2009) (0)
Abstract 4407: Neutralizing monoclonal antibody to periostin (PN) inhibits ovarian tumor metastatic growth in animal models (2010) (0)
The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in breast cancer cells (2006) (0)
Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials (2023) (0)
Opening and introductory remarks (2006) (0)
Abstract 710: Gene expression profile of the Wnt signaling pathway in trastuzumab resistant breast cancer cells (2011) (0)
Abstract A26: Protein phosphatase 4 (PP4) as a potential therapeutic target gene for BRAF wild type melanoma (2015) (0)
Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer (2015) (0)
Expression of Haras Oncogene Products in Human Neuroblastomas and the Significant Correlation with a Patient ' s Prognosis 1 (2006) (0)
A decade of docetaxel in the treatment of early-stage breast cancer: evolution or revolution? Satellite symposium at the EBCC 5 meeting, (2006) (0)
1049 POSTER Increased Amplification of HER2 in a Cell Line Model of Acquired Lapatinib Resistance (2011) (0)
P2.01-078 Frequent High TIM-3 (HAVCR2) Expression in Resected NSCLC Specimens, Most Notably in Adenocarcinoma Histology: Topic: Marker for Prognosis (2017) (0)
Loss Is Associated with Worse Outcome in HER 2-Ampli fi ed Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance (2015) (0)
Abstract 6258: The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024 (2023) (0)
Abstract A96: Breast tumor subtypes and survival outcomes in African American and Latina patients in South Los Angeles (2010) (0)
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 (2016) (0)
Recent advances in the molecular classification of ovarian cancer (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Gynecological cancers) (2011) (0)
Abstract 743: Potent anti-tumor activity of the MEK1/2 inhibitor MEK162 in human non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) cell lines (2014) (0)
Use of inhibitors of the receptor of platelet-derived growth factors for preparing a medicament for the treatment of cancer (1995) (0)
Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers (2023) (0)
Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ). (2021) (0)
Molecular profiling and comparative genomic hybridization analysis in human melanoma cell lines and identification of BRAF amplification in a PLX4032 acquired resistance cell line. (2012) (0)
Short Communication Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma (2009) (0)
A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors (2018) (0)
Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials (2023) (0)
Abstract 2201: Involvement of somatic mutations in silencing cystatin E/M tumor suppressor gene in breast cancer (2011) (0)
DAMD 1794-J-4118 TITLE : Biologic Effects of HER-2 / Neu Gene Overexpression and Agonists and Antagonists to the Receptor in Human Breast Cancer (0)
Process for the determination or isolation of malignant human cells, antibody or antigenic oligopeptide and method for manufacturing the same (1983) (0)
Meeting Abstracts Breast Cancer Research 2008 (2008) (0)
Cancer Research in the 21st Century. (2016) (0)
Author's response to reviews Title: Caspase 8 and Maspin are downregulated in Breast Cancer Cells due to CpG Island Promoter Methylation Authors: (2009) (0)
Enzyme-Catalyzed Antimicrobial Activation (2002) (0)
Abstract 4602: Effect of estrogen receptor antagonistic drugs on expression and regulation of fatty acid synthase (FAS) in ER+ breast cancer cell lines (2010) (0)
Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies (2022) (0)
Genes a expression differentielle associes a la surexpression de her-2/neu (2000) (0)
Inhibition of the HER-2/neu Oncogene (2003) (0)
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells (2007) (0)
Efficacy a nd S afety o f T rastuzumab a s a S ingle A gent i n First-Line T reatment o f HER2 -Overexpressing M etastatic Breast C ancer (2011) (0)
Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. (2023) (0)
Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET (2022) (0)
A careful reassessment of anthracycline use in curable breast cancer (2021) (0)
Development of models of both acquired and de novo resistance to Herceptin (2008) (0)
498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma (2014) (0)
Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy. (2022) (0)
Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (0)
Abstract 297: Activity of carfilzomib (CFZ) alone and in combination with cytarabine and chloroquine diphosphate (CHQ) in acute myeloid leukemia (AML) (2019) (0)
Abstract 773: Early detection of ovarian cancer using cell-free DNA fragmentomes (2023) (0)
UCLA/USC Tumor Tissue Bank. (1997) (0)
Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers (2023) (0)
Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ). (2022) (0)
Follow-up from Dennis Slamon about Article in 7/25/08 issue (2008) (0)
Akt1 overexpression in HER2/neu positive breast tumors in African American and Latina women may contribute to poor disease free and overall survival (2007) (0)
PG 5.01 Targeting CDK 4–6 pathway (2015) (0)
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors (2018) (0)
Balance of efficacy and toxicity varies with trastuzumab for early breast cancer (2007) (0)
Abstract 4751: Identification of mechanism involved in mesothelial clearance by ovarian tumor spheroids (2011) (0)
RNA viruses and cancer (1986) (0)
Abstract 136: Phospho-S6 levels correlate with response to Copanlisib (BAY 80-6946) in multiple myeloma (2017) (0)
558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer (2012) (0)
T Cell Costimulatory Pathway Antibody Specificity and Ability to Activate Via A B 7 . 1-Antibody Fusion Protein (1998) (0)
Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial (2020) (0)
Abstract 3453: Selective sensitivity of Ewing's Sarcoma to the PARP inhibitor BMN 673. (2013) (0)
Abstract 4570: Functional analysis of gene expression profiling of primary and metastatic melanoma: Possible implications from BRAF mutant and wild-type cell lines (2012) (0)
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial (2019) (0)
P1.05-003 Coexpression of CD8a and PD-L1 Frequently Observed in Resected NSCLC Tumors from Smokers: Topic: Translational Research and Biomarkers (2017) (0)
Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer (2020) (0)
Biologic Effects of HER-2/Neu Gene Overexpression and Agonists and Antagonists to the Receptor in Human Breast Cancer (1995) (0)
Abstract P4-10-12: Characterizing the tumor and immune microenvironment through treatment to predict response to neoadjuvant HER2-targeted therapy using the Digital Spatial Profiler (2020) (0)
Abstract 6254: The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445 (2023) (0)
Cancer biology: Editorial overview (1992) (0)
Abstract 2978: Clinical evaluation of lapatinib induced BCL-2 adaptive responses (2019) (0)
Abstract 613: Increased PI3K/AKT activity, which confers resistance to trastuzumab, can be overcome by lapatinib (2010) (0)
Abstract 454: Evaluating the progression of cutaneous melanoma by the molecular immune response of the sentinel lymph node (2015) (0)
Phase I and pharmacokinetic (PK) Study of CP-724,714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor. (2004) (0)
Erratum: Shaping the future of biomarker research (Nature Reviews Cancer (2007) 7, (309-315)) (2007) (0)
Abstract 3023: Fatty acid synthase (FASN) inhibitors synergize with carfilzomib (CFZ) in acute myeloid leukemia (AML) and multiple myeloma (MM) (2022) (0)
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. (2020) (0)
Reply to R. Simon (2011) (0)
DietaryNutrientIntakesand SlightAlbuminuria in Peopleat Least40 Years Old (1993) (0)
Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers (2022) (0)
Abstract P3-03-13: Long-term heart failure risk of trastuzumab with or without anthracyclines in early stage breast cancer: A SEER-Medicare Database Analysis (2023) (0)
Efficacy, Safety, and Patient-Reported Outcomes of Postmenopausal Women with Advanced Breast Cancer Receiving Ribociclib + Fulvestrant: Results from MONALEESA-3 (2018) (0)
HER-2 / neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer 1 (2001) (0)
MP88-11 THERAPEUTIC EFFECTS OF A MICRORNA-21 CHEMICAL INHIBITOR ON BLADDER CANCER PRECLINICAL MODELS (2016) (0)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer (2020) (0)
Substantial removal of human malignant cell from mixture of human malignant and normal cells (1992) (0)
Abstract 1206: Preclinical evaluation of targeting Notch-3 in breast cancer (2016) (0)
Abstract 3668: Inhibition of HSP90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer (2012) (0)
Human T-cell leukemia virus x gene. (1985) (0)
Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer (2011) (0)
Abstract 1595: The poly(ADP-ribose) polymerase inhibitor BMN 673 has single agent activity and augments cytotoxicity of radiation in human head and neck tumor cell linein vitro: a novel strategy for radiosensitization in head and neck cancer. (2013) (0)
Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial (2015) (0)
Update from the 29th Annual San Antonio Breast Cancer Symposium (2006) (0)
Abstract B232: Preclinical evaluation of AMG479 a fully human insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells (2009) (0)
Abstract 2336: Pan-cancer analysis of NAMPT inhibitors reveals unique sensitivities to multiple NAMPT inhibitors in several cancer types (2022) (0)
Identification of Conserved Amino Acids in the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor a Subunit Critical for Function (2001) (0)
Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC). (2018) (0)
Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma (2016) (0)
Use of inhibitors of the platelet-fragments of muscles growth factor receptor for the manufacture of a lægmiddel to Behan (1995) (0)
Abstract 3633: eEF2 in acquired lapatinib resistance in HER2 positive breast cancer cells (2010) (0)
Effect of PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, on proliferation in renal cell carcinoma at nanomolar concentrations and prediction of sensitivity by molecular markers. (2013) (0)
Abstract 1795: Potent anti-tumor activity of talazoparib (BMN673) in combination with radiation for squamous cell carcinoma of the head and neck (2015) (0)
Resource Integrated Genomic , Epig enomic , and Expression Analyses of Ovarian Cancer Cell Lines Graphical (2018) (0)
Abstract PD3-11:HER2/ERBB2status in “HER2equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci (2019) (0)
Exisulind and CP461 inhibit cell growth, induce apoptosis, and have synergy with herceptin and taxotere in breast cancer cells (2001) (0)
Abstract 2736: Regulation of cytokinesis by polo-like kinase 4 (2016) (0)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. (2023) (0)
The comparative molecular biology of HTLV-I and HTLV-II. (1984) (0)
The interferon mechanism: action of the translation inhibatory- directed ribosome. (1969) (0)
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive with (2018) (0)
Signal transduction : a technical overview. (2001) (0)
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE) (2023) (0)
Moesin, caveolin 1 and yes-associated protein markers of response to dasatinib in breast cancers. (2006) (0)
Copanlisib Has Activity As a Single Agent and in Combination with Carfilzomib and Response Correlates with Phospho-S6 Level (2017) (0)

This paper list is powered by the following services:

Other Resources About Dennis Slamon

en.wikipedia.org

What Schools Are Affiliated With Dennis Slamon?

Dennis Slamon is affiliated with the following schools:

Dennis Slamon's Academic­Influence.com Rankings